MacroGenics, Inc. (MGNX)
MGNXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$2.20
-0.0900 (-3.93%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $140.60m
- P/E
- –
- EPS, last 4 quarters
- $-1.41
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.32 to $5.08
- Average volume
- –
- Previous close
- $2.29
Analysts
4 coveringHold2 buy, 2 hold, 0 sell
Targets a year out average $7.00, +218.2% from here
Earnings
next estimate $-0.3900Next report
Dec 2025
+47.6%
Mar 2026
-1.8%
Jun 2026
+20.6%
Sep 2026
-240.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $82.58m | $20.77m | $18.78m | $18.67m |
| Gross profit | $46.58m | $11.24m | $28.31m | $18.67m |
| Operating income | $3.37m | -$33.44m | -$18.38m | -$20.30m |
| Net income | -$14.15m | -$36.77m | $19.52m | -$20.08m |
Last four quarters: revenue $140.81m, margin -36.6%, free cash flow -$41.34m
News
8 latest- MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue EstimatesZacks · 1 day ago
- MacroGenics, Inc. Appoints Michael Vasconcelles and Emil Kuriakose to Board of DirectorsFintel · Nov 3, 2026
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals RTTNews · Oct 30, 2026
- ResMed (RMD) Beats Q1 Earnings and Revenue EstimatesZacks · Oct 29, 2026
- MacroGenics Expands Lorigerlimab Trial After Interim Gynecologic Cancer Results; RTTNews · Oct 26, 2026
- MacroGenics Expands Lorigerlimab Trial After Interim Gynecologic Cancer Results; Stock Down RTTNews · Oct 26, 2026
- MacroGenics' Lorigerlimab Shows 25% Response Rate In Clear Cell Gynecologic Cancer RTTNews · Oct 26, 2026
- MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNFintel · Oct 23, 2026
The company
MacroGenics (the Company) is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- macrogenics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.